twst stock: Twist Bioscience (TWST) Guide

Twist Bioscience Corporation (TWST)

Key term: twst stock

Lead summary

Twist Bioscience (ticker: TWST) is a publicly traded company on the Nasdaq focused on synthetic DNA manufacturing and genomics tools. This guide explains what twst stock represents, Twist’s core technology and products, its markets and customers, recent financial and market data, risks, and how investors and researchers typically follow the name. The article is written for beginners and informed readers who want a factual, source-based overview without investment advice.

Note: twst stock appears throughout this article as the primary search keyword and is used in accordance with current public reporting.

Company overview

Twist Bioscience is a synthetic biology company that develops and sells synthetic DNA products and related genomics tools to customers across biopharma, diagnostics, academic research and industrial biotech. The company’s offerings include synthetic genes and oligonucleotides, oligo pools for library construction and DNA data storage experiments, next-generation sequencing (NGS) library prep kits, plasmid preparations, and molecular controls for infectious disease testing.

Twist emphasizes high-throughput DNA synthesis using a proprietary semiconductor-based platform to deliver large volumes of sequence-accurate DNA. Headquartered in South San Francisco, California, Twist operates manufacturing and R&D facilities and serves customers globally. The workforce size has grown with the business, and the company reports several hundred to low‑thousand employees in its public disclosures and investor materials.

History

Founding and early development

Twist Bioscience was founded to commercialize a DNA synthesis approach that uses silicon-based production methods. The company incorporated and scaled its technology in the 2010s, developing a platform aimed at lowering costs and improving throughput for synthetic DNA compared with traditional column- or plate-based synthesis.

IPO and public listing

Twist completed an initial public offering and listed on the Nasdaq under the ticker TWST. Since listing, twst stock has been covered by market data providers and financial news outlets. Over time the company has announced product expansions, manufacturing capacity increases, strategic partnerships, and investments in automation and quality control to support higher-volume customers.

As of Jan 27, 2026, according to company investor relations and public market data, twst stock remains listed on the Nasdaq exchange and is tracked by major financial data services.

Technology and products

DNA synthesis platform and manufacturing

The core technical differentiator for Twist is its semiconductor-based DNA synthesis platform. Instead of traditional column or plate syntheses, Twist uses patterned silicon chips and electrochemical deprotection steps to parallelize the synthesis of thousands to millions of oligonucleotides per run. This architecture is designed to increase throughput, reduce cost per base, and enable high-complexity oligo pools used in large-scale screening, directed evolution, gene assembly and emerging DNA data storage experiments.

Key practical benefits emphasized by Twist include:

• High parallelization enabling large oligo pool complexity.
• Improved accuracy and reduced error profiles through process controls and bioinformatics quality checks.
• Scalable manufacturing designed to serve both research-scale and commercial customers.

Product lines

Major product categories sold to customers include:

• Synthetic oligonucleotides and genes: individually synthesized oligos and assembled gene constructs used in cloning, protein engineering, and assay development.
• Oligo pools and libraries: complex pools used for CRISPR screens, directed evolution, library screening, and other high-throughput applications.
• NGS library prep kits and panels: consumables and panels to streamline sample preparation for next-generation sequencing workflows.
• Plasmid preparations and cloning services: ready-to-use plasmids and related services for molecular biology work.
• Molecular controls and assay panels: controls for respiratory panels and other diagnostic assays, used by clinical labs and test manufacturers.

Applications range from drug discovery and biologics engineering to diagnostics and agricultural biotech. Twist also highlights collaborations exploring DNA as a storage medium and expanding automated workflows.

R&D and innovation

Twist invests in process improvements to increase speed, fidelity, and scale of synthesis. R&D priorities commonly noted in company disclosures and investor presentations include automation of end-to-end workflows, integration with computational design tools, improving synthesis yield and accuracy, and expanding product breadth to capture downstream workflows such as library prep and plasmid services.

Ongoing innovation aims to reduce time-to-result for customers and to support commercial-scale customers in therapeutics and diagnostics.

Markets, customers and use cases

Twist serves multiple end markets:

• Biopharmaceutical and therapeutics R&D: customers use synthetic DNA for lead discovery, antibody engineering, vaccine design, and biologics optimization.
• Diagnostics and clinical testing: molecular controls, panels and reagents are used in clinical labs and diagnostic manufacturers.
• Academic and government research: universities and research institutes use Twist products for publications and basic research.
• Contract research organizations (CROs) and biotech service providers: these organizations integrate synthetic DNA into service offerings.
• Industrial biotech and agriculture: synthetic biology applications include strain engineering, enzyme discovery and crop trait development.
• Emerging use case — DNA data storage: academic and commercial experiments use high-density oligo pools to encode digital information.

Customers range from small research labs to large pharmaceutical companies and diagnostic manufacturers. The company positions its product portfolio to serve both high-complexity research needs and regulated diagnostic use cases.

Partnerships and collaborations

Twist has announced multiple strategic collaborations and partnerships over time. These alliances often focus on co-development of assays, distribution of molecular controls, or technical integration with sequencing and automation partners. Partnerships serve to expand market access, validate products with end users, and accelerate adoption in regulated settings such as clinical diagnostics.

Notable collaboration types include:

• Co-development agreements with diagnostic companies for panels and controls.
• Research partnerships with academic labs and government research programs.
• Distribution and commercialization collaborations to expand geographic reach.

These strategic relationships are important for validating performance, increasing sales channels, and raising the profile of twst stock among institutional investors following adoption milestones.

Corporate governance and management

Twist’s executive leadership and board provide operational and technical oversight. The company’s CEO, Emily M. Leproust, is a commonly cited public figure associated with Twist’s founding and leadership. Public filings and investor materials list board members with experience across biotech, life science tools and public markets.

The company’s headquarters are in South San Francisco, California, with manufacturing and R&D facilities positioned to support global customers. Employee counts and corporate headcount are reported in periodic SEC filings and investor presentations; interested readers should consult the latest Form 10‑K or investor relations updates for precise figures.

Financial information

All financial data below is presented to summarize typical metrics reported by public sources. For precise and up-to-date figures consult the company’s latest SEC filings and the market-data services listed in References.

Recent financial performance

As of Jan 27, 2026, reported trailing revenues for Twist have been in the range of several hundred million dollars annually, with recent periods showing year-over-year revenue growth driven by product mix expansion and demand from diagnostics and biopharma customers. The company has historically reported net losses as it invests in manufacturing capacity, R&D and commercial scaling.

For example, public filings detail periods where revenue growth outpaced gross margin expansion but operating expenses (R&D and SG&A) contributed to continuing net losses. Analysts commonly highlight revenue growth as the primary near-term success metric while monitoring path to profitability through margin improvement and operating leverage.

Key financial metrics

Important metrics available from public market-data providers and filings include:

• Revenue growth rate (year-over-year percentage).
• Gross margin and adjusted gross margin reflecting product mix.
• Operating margin and adjusted EBITDA metrics used by analysts.
• Earnings per share (EPS, TTM) showing trailing profitability (often negative in recent periods).

As of the reporting date above, public coverage shows gross margins and operating metrics improving gradually but still impacted by scale-up costs in manufacturing. Exact numeric values change quarterly; readers should verify the latest quarterly report for current figures.

Capital structure

Twist’s capital structure includes publicly traded common shares, any outstanding convertible securities, and a mix of cash and debt on the balance sheet. Company disclosures report cash and cash equivalents, short-term investments, and any long-term debt. Historically, Twist has funded growth through equity offerings and operating cash flows supplemented by capital raises when needed to support manufacturing expansion.

Investors following twst stock monitor dilution risk from share issuance, cash runway metrics, and any debt covenants that could affect liquidity.

Stock and market data

Exchange and identifiers

• Ticker: TWST
• Exchange: Nasdaq
• ISIN and other identifiers are published in company filings and market-data services.

Trading statistics

Trading statistics for twst stock reported by market data platforms include market capitalization, average daily volume, free float, and the 52‑week price range. For example, public market summaries reported a 12‑month trading range roughly in the low‑$20s to mid‑$50s per share in the most recent 12‑month window noted by sources. Daily average volume and float metrics vary over time and are available from financial data providers and the Nasdaq listing page.

As of Jan 27, 2026, several market-data services report market capitalization in the multi‑billion to sub‑billion range depending on share price movements; please consult the latest market quote for real-time values.

Analyst coverage and price targets

twst stock is covered by sell‑side analysts and independent research firms. Consensus ratings across analysts have at times skewed toward Buy/Hold depending on expectations for revenue growth and margin expansion. Price-target ranges vary by firm and are updated with quarterly results and material company announcements. For the latest consensus and individual analyst notes, consult market-data providers and the company’s investor relations disclosures.

Dividends and buybacks

Twist does not pay a cash dividend and historically has not had a broad share‑repurchase program. Capital allocation to date has prioritized reinvestment in manufacturing, R&D and commercialization rather than returning capital to shareholders. Any future dividend or buyback decisions would be disclosed in company filings.

Options, short interest and liquidity

Options trading exists for twst stock on listed options marketplaces, and short interest metrics are tracked by public data providers. At times, short interest has been notable for names in the life‑science tools sector, and elevated short float can contribute to intraday volatility. Liquidity is typically sufficient for retail and institutional trading, though volume can vary with news events and broader market conditions.

Recent events and news

This section summarizes the types of events that typically move twst stock and notes recent public items as of the reporting date:

• Earnings releases and quarterly results: Revenue beats or misses and guidance revisions materially affect trading in twst stock.
• Product launches: New plasmid preparations, expanded NGS kits, or diagnostic control panels often appear in press releases and investor presentations; such launches can influence customer adoption and analyst sentiment.
• Investor conferences and presentations: Participation at healthcare and biotech conferences (for example, major annual investor healthcare events) provides visibility for strategy updates.
• Regulatory, legal or governance updates: Public companies sometimes disclose inquiries, routine litigation, or other regulatory matters in filings; these are material and reported to investors.

As of Jan 27, 2026, specific item reporting examples include quarterly earnings and product announcements summarized in the company’s investor relations materials and covered by market-data platforms. Readers should review the latest press releases and the most recent Form 10‑Q/10‑K for complete, time-stamped details.

Risks and criticisms

Investors and industry observers typically consider the following risks when evaluating twst stock:

• Profitability challenges: Ongoing investment in capacity and R&D can keep the company unprofitable in the near term.
• Market cyclicality: Biotech and diagnostics spending can be cyclical, affecting demand for synthetic DNA products.
• Competition: Other DNA synthesis and genomics tools providers compete on price, throughput and service quality.
• Manufacturing and supply chain risks: Scaling semiconductor-style synthesis at commercial volumes carries operational risk.
• Regulatory and quality risks: Diagnostic and clinical customers require high-quality, validated products; quality issues could affect reputation and revenue.
• Liquidity and valuation volatility: Like many small‑to‑mid cap life science names, twst stock can experience significant price swings.

Additionally, public scrutiny from investors or shareholder litigation inquiries can arise in any listed company; such matters are disclosed in regulatory filings and news reports when they occur.

Intellectual property and competitive position

Twist’s IP portfolio and proprietary synthesis process are central to its competitive positioning. Patents and trade secrets around semiconductor-based synthesis, process controls, and automation help protect market share. Competitors range from established oligo and gene providers to new entrants aiming to scale alternative synthesis methods.

Analysts and customers evaluate Twist’s competitive edge based on throughput, error rates, cost per base, and the ability to commercialize downstream workflows such as plasmids and NGS kits.

Environmental, social and governance (ESG)

Twist publishes disclosures on workforce practices, governance and product safety. ESG topics relevant to the company include biosafety protocols in manufacturing, responsible handling of biological materials, employee health and safety, diversity and inclusion, and governance structures for a publicly traded company.

Investors focused on ESG may review the company’s public sustainability and governance disclosures, as well as any third‑party assessments addressing biosafety and environmental impact.

See also

• Synthetic biology
• DNA synthesis
• Next‑generation sequencing (NGS)
• Genomics reagent and tools companies (peer list)

References

This article draws on public company disclosures and market-data coverage. Primary sources include Twist Bioscience investor relations materials and SEC filings; market summaries and trading data published by major financial outlets; and coverage by specialist market-data providers. Example reference outlets include (no external links provided here):

• Twist Bioscience investor relations and SEC filings (Form 10‑Q/10‑K)
• Nasdaq company page and market summaries
• Yahoo Finance and TradingView market data and quote pages
• CNN Markets and financial press coverage
• Seeking Alpha and analyst commentary
• StockAnalysis, Finviz and Public.com market snapshots
• Company press releases and investor presentation decks

As of Jan 27, 2026, reported market commentary and data were summarized from the above types of sources, and readers should consult the most recent filings and market quotes for current figures.

External links

Listed external resources commonly consulted for twst stock information include the company’s official website and investor relations pages, the SEC EDGAR database for filings, and market-data providers for live quotes and analyst coverage. For trading access, users can consider the Bitget exchange and Bitget Wallet for custody and trading convenience. (No external URLs are provided in this article.)

How to follow twst stock and next steps

• Monitor quarterly earnings and the company’s investor presentation for updates on revenue, gross margins and operating expenses.
• Review SEC filings for audited figures and risk disclosures.
• Track market-data pages for real-time price, volume and analyst updates.
• For traders and investors seeking execution, Bitget provides market access and custody; consider using Bitget Wallet for secure storage of account credentials and to manage trades. Remember: this article is informational and not investment advice.

Notes on data and reporting

• As of Jan 27, 2026, public outlets including company investor relations pages and market-data services report the metrics and product descriptions summarized above.
• All numerical figures and market statistics change over time; verify live quotes and the latest filings before making decisions.

Final thoughts — further exploration

If you want to track twst stock more closely, set up quote alerts on your market-data platform and subscribe to Twist Bioscience investor alerts. To trade or custody shares, Bitget offers trading pairs and wallet tools to manage positions. Explore company filings for the most authoritative financial information and consult licensed financial professionals for personalized advice.

To learn more about trading and secure custody options for twst stock, explore Bitget features and the Bitget Wallet.